MetaCap

Keros Therapeutics Insider Trades

NASDAQ: KROSHealth CareBiotechnology: Pharmaceutical PreparationsUSD

11.08-0.31 (-2.72%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Last 12 months

Purchases
6 · $75.77K
Sales
17 · $540.78K
Shares bought / sold
7.00K / 40.33K
Net activity
Net selling $465,009

Keros Therapeutics insider activity

Over the last 12 months, Keros Therapeutics insiders reported 31 transactions on SEC Form 4: 6 open-market purchases and 17 sales. Insiders bought $75,770 and sold $540,779 worth of stock, for net insider selling of $465,009. The largest seller was Cho Esther, with $123,731 in reported sales.

The most recent filing shows Newton Charles W. (Director) selling 491 shares at $10.83 on Nov 17, 2026. Insider sales are common for compensation, tax and diversification reasons, while open-market purchases are rarer; tracking both helps put KROS's ownership changes in context.

Summary generated from market data by MetaCap's automated system. Methodology

KROS insider transactions

Keros Therapeutics insider transactions
DateInsiderTypeSharesValueFiling
Nov 17, 2026Prener AnneDirectorSale142$1.57KForm 4
Nov 17, 2026Prener AnneDirectorSale433$4.66KForm 4
Nov 17, 2026Newton Charles W.DirectorSale60$663Form 4
Nov 17, 2026Newton Charles W.DirectorSale491$5.32KForm 4
Nov 12, 2026Prener AnneDirectorSale574$5.62KForm 4
Aug 18, 2026Newton Charles W.DirectorSale551$5.68KForm 4
Aug 18, 2026Cho EstherChief Legal OfficerSale4,485$46.15KForm 4
Aug 18, 2026Lerner Lorena RaquelChief Scientific OfficerSale3,568$36.71KForm 4
Aug 18, 2026Tanini AnnitaCorp. Controller & VP, FinanceSale1,224$12.59KForm 4
Aug 17, 2026BIENAIME JEAN JACQUESDirectorBuy1,000$10.27KForm 4
Jul 15, 2026BIENAIME JEAN JACQUESDirectorBuy1,000$10.61KForm 4
Jul 1, 2026Prener AnneDirectorAward13,786—Form 4
Jun 15, 2026BIENAIME JEAN JACQUESDirectorBuy1,000$10.19KForm 4
Jun 11, 2026Newton Charles W.DirectorSale550$5.52KForm 4
Jun 4, 2026Seth AlpnaDirectorSale2,625$28.14KForm 4
Jun 4, 2026Knowles JuliusDirectorSale2,625$28.17KForm 4
Jun 4, 2026Farzan NimaDirectorSale2,625$28.17KForm 4
Jun 3, 2026Knowles JuliusDirectorAward7,142—Form 4
Jun 3, 2026BIENAIME JEAN JACQUESDirectorAward7,142—Form 4
Jun 3, 2026Farzan NimaDirectorAward7,142—Form 4
Jun 3, 2026GRAY MARY ANNDirectorAward7,142—Form 4
Jun 3, 2026Seth AlpnaDirectorAward7,142—Form 4
May 15, 2026BIENAIME JEAN JACQUESDirectorBuy1,000$10.58KForm 4
Apr 15, 2026BIENAIME JEAN JACQUESDirectorBuy1,000$11.70KForm 4
Apr 2, 2026Seehra JasbirCHIEF EXECUTIVE OFFICEROption exercise55,000$16.50KForm 4
Mar 9, 2026Newton Charles W.DirectorAward13,215—Form 4
Mar 9, 2026BIENAIME JEAN JACQUESDirectorBuy2,000$22.42KForm 4
Feb 19, 2026Seehra JasbirCHIEF EXECUTIVE OFFICERSale7,015$113.43KForm 4
Feb 18, 2026Regnante KeithCHIEF FINANCIAL OFFICERSale4,739$77.48KForm 4
Feb 18, 2026Cho EstherSVP, General CounselSale4,745$77.58KForm 4
Feb 18, 2026Lerner Lorena RaquelChief Science OfficerSale3,873$63.32KForm 4
Nov 21, 2025Knowles JuliusDirectorDisposition130,494$2.32MForm 4
Nov 21, 2025Knowles JuliusDirectorDisposition191,527$3.40MForm 4
Nov 21, 2025GORDON CARL LDirectorDisposition74,465$1.32MForm 4
Nov 21, 2025GORDON CARL LDirectorDisposition140,057$2.49MForm 4
Nov 21, 2025ORBIMED ADVISORS LLC & OrbiMed Capital GP VII LLC & OrbiMed Genesis GP LLCDirectorDisposition74,465$1.32MForm 4
Nov 21, 2025ORBIMED ADVISORS LLC & OrbiMed Capital GP VII LLC & OrbiMed Genesis GP LLCDirectorDisposition140,057$2.49MForm 4
Oct 15, 2025ADAR1 Capital Management, LLC & ADAR1 Partners, LP & ADAR1 Capital Management GP, LLC & Schneeberger Daniel10% OwnerSale743,358$13.19MForm 4
Oct 15, 2025ADAR1 Capital Management, LLC & ADAR1 Partners, LP & ADAR1 Capital Management GP, LLC & Schneeberger Daniel10% OwnerSale254,669$4.52MForm 4
Oct 15, 2025ADAR1 Capital Management, LLC & ADAR1 Partners, LP & ADAR1 Capital Management GP, LLC & Schneeberger Daniel10% OwnerSale4,391,237$77.94MForm 4
Oct 15, 2025Pontifax Management 4 G.P. (2015) Ltd. & Pontifax (Israel) IV, L.P. & Pontifax (Cayman) IV L.P. & Pontifax (China) IV L.P. & Pontifax Late Stage Fund L.P. & Pontifax Late Stage GP Ltd. & Kariv Tomer & Nussbaum Ran10% OwnerSale155,262$2.76MForm 4
Oct 15, 2025Pontifax Management 4 G.P. (2015) Ltd. & Pontifax (Israel) IV, L.P. & Pontifax (Cayman) IV L.P. & Pontifax (China) IV L.P. & Pontifax Late Stage Fund L.P. & Pontifax Late Stage GP Ltd. & Kariv Tomer & Nussbaum Ran10% OwnerSale1,226,412$21.77MForm 4
Oct 15, 2025Pontifax Management 4 G.P. (2015) Ltd. & Pontifax (Israel) IV, L.P. & Pontifax (Cayman) IV L.P. & Pontifax (China) IV L.P. & Pontifax Late Stage Fund L.P. & Pontifax Late Stage GP Ltd. & Kariv Tomer & Nussbaum Ran10% OwnerSale1,121,045$19.90MForm 4
Oct 15, 2025Pontifax Management 4 G.P. (2015) Ltd. & Pontifax (Israel) IV, L.P. & Pontifax (Cayman) IV L.P. & Pontifax (China) IV L.P. & Pontifax Late Stage Fund L.P. & Pontifax Late Stage GP Ltd. & Kariv Tomer & Nussbaum Ran10% OwnerSale2,284,612$40.55MForm 4
Sep 3, 2025Seehra JasbirCHIEF EXECUTIVE OFFICERAward90,500—Form 4
Jun 20, 2025ADAR1 Capital Management, LLC & ADAR1 Partners, LP & ADAR1 Capital Management GP, LLC & Schneeberger Daniel10% OwnerOption exercise200$14.00KForm 4
Jun 20, 2025ADAR1 Capital Management, LLC & ADAR1 Partners, LP & ADAR1 Capital Management GP, LLC & Schneeberger Daniel10% OwnerOption exercise1,400$98.00KForm 4
Jun 20, 2025ADAR1 Capital Management, LLC & ADAR1 Partners, LP & ADAR1 Capital Management GP, LLC & Schneeberger Daniel10% OwnerOption exercise100$6.00KForm 4

Transaction codes follow SEC Form 4: P = open-market purchase, S = open-market sale, A = grant or award, M = option exercise, F = shares withheld for taxes. About Form 4

Related